Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?

European Respiratory Journal

Volumn 33, Issue 3, 2009, Pages 468-480

  Quaak, M ^a,b   Van Schayck, C P ^a   Knaapen, A M ^b   Van Schooten, F J ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Addiction; Pharmacogenetics; Smoking cessation

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; CLONIDINE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; NALOXONE; NALTREXONE; NICOTINE; NORTRIPTYLINE; OPIATE RECEPTOR; PLACEBO; VARENICLINE; VENLAFAXINE;

ACUPUNCTURE; ASTHMA; BEHAVIOR THERAPY; CHRNA4 GENE; CHRNA5 GENE; CHRNA7 GENE; CHRNB1 GENE; CHRNB2 GENE; CHRNB3 GENE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYP2A6 GENE; CYP2D6 GENE; DOPAMINERGIC SYSTEM; DRD1 GENE; DRD2 GENE; DRD4 GENE; DRD5 GENE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ELECTROSTIMULATION; GENETIC VARIABILITY; GROUP THERAPY; HUMAN; HUMAN GENOME; LOW LEVEL LASER THERAPY; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SEROTONINERGIC SYSTEM; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ARYL HYDROCARBON HYDROXYLASES; DOPAMINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MODELS, GENETIC; OXIDOREDUCTASES, N-DEMETHYLATING; SEROTONIN; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 61649090049     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00056908     Document Type: Review

References (149)

1. Curbing the epidemic: governments and the economics of tobacco control. The World Bank. Tob Control 1999; 8: 196-201.
2. Steptoe A, Wardle J, Cui W, et al. An international comparison of tobacco smoking, beliefs and risk awareness in university students from 23 countries. Addiction 2002; 97: 1561-1571.
3. The world health report 2003 - shaping the future. Geneva, World Health Organization, 2003.
4. Guindon GE, Boisclair D. Past, current and future trends in tobacco use. HNP discussion paper. Econcomics of tobacco control paper no. 6. Washington, The World Bank, 2003.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
6. Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92: 990-996.
7. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer 2005; 92: 426-429.
8. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355-358.
9. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2002; 3: CD001292.
10. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005; 2: CD001007.
11. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
12. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
13. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD006103.
14. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006; 4: CD003086.
15. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000058.
16. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2006; 1: CD000009.
17. Kaprio J, Hammar N, Koskenvuo M, Floderus-Myrhed B, Langinvainio H, Sarna S. Cigarette smoking and alcohol use in Finland and Sweden: a cross-national twin study. Int J Epidemiol 1982; 11: 378-386.
18. Heath AC, Cates R, Martin NG, et al. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. J Subst Abuse 1993; 5: 221-246.
19. Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993; 18: 19-34.
20. True WR, Heath AC, Scherrer JF, et al. Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277-1287.
21. Kendler KS, Neale MC, Sullivan P, Corey LA, Gardner CO, Prescott CA. A population-based twin study in women of smoking initiation and nicotine dependence. Psychol Med 1999; 29: 299-308.
22. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res 1999; 1: Suppl. 2, S51-S57.
23. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT. The genetic determinants of smoking. Chest 2003; 123: 1730-1739.
24. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
25. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
26. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
27. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
28. The health consequences of smoking: a report of the Surgeon General. Atlanta, U.S. Department of Health and Human Services, 2004. Available from http://www.cdc.gov/tobacco/data-statistics/sgr/sgr-2004/index.htm.
29. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309: 901-911.
30. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 67-86.
31. Willemse BWM, Postma DS, Timens W, Ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476.
32. Bartal M. COPD and tobacco smoke. Monaldi Arch Chest Dis 2005; 63: 213-225.
33. Hylkema MN, Sterk PJ, de Boer WI, Postma DS. Tobacco use in relation to COPD and asthma. Eur Respir J 2007; 29: 438-445.
34. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
35. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9: 687-695.
36. Beasley R, Pearce N, Crane J. International trends in asthma mortality. Ciba Found Symp 1997; 206: 140-150.
37. Sunyer J, Anto JM, Tobias A, Burney P. Generational increase of self-reported first attack of asthma in fifteen industrialized countries. European Community Respiratory Health Study (ECRHS). Eur Respir J 1999; 14: 885-891.
38. Beeber SJ. Parental smoking and childhood asthma. J Pediatr Health Care 1996; 10: 58-62.
39. Cook DG, Strachan DP. Health effects of passive smoking. 10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999; 54: 357-366.
40. Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch Chest Dis 2001; 56: 349-353.
41. Jindal SK, Gupta D. The relationship between tobacco smoke and bronchial asthma. Indian J Med Res 2004; 120: 443-453.
42. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-833.
43. Tyc VL, Throckmorton-Belzer L. Smoking rates and the state of smoking interventions for children and adolescents with chronic illness. Pediatrics 2006; 118: e471-e487.
44. Tager IB. The effects of second-hand and direct exposure to tobacco smoke on asthma and lung function in adolescence. Paediatr Respir Rev 2008; 9: 29-37.
45. Wang L, Pinkerton KE. Detrimental effects of tobacco smoke exposure during development on postnatal lung function and asthma. Birth Defects Res C Embryo Today 2008; 84: 54-60.
46. Lemiere C, Boulet LP. Cigarette smoking and asthma: a dangerous mix. Can Respir J 2005; 12: 79-80.
47. Thomson NC, Spears M. The influence of smoking on the treatment response in patients with asthma. Curr Opin Allergy Clin Immunol 2005; 5: 57-63.
48. Livingston E, Thomson NC, Chalmers GW. Impact of smoking on asthma therapy: a critical review of clinical evidence. Drugs 2005; 65: 1521-1536.
49. Xian H, Scherrer JF, Madden PA, et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 2003; 5: 245-254.
50. Pergadia ML, Heath AC, Martin NG, Madden PA. Genetic analyses of DSM-IV nicotine withdrawal in adult twins. Psychol Med 2006; 36: 963-972.
51. Rossing MA. Genetic influences on smoking: candidate genes. Environ Health Perspect 1998; 106: 231-238.
52. Arinami T, Ishiguro H, Onaivi ES. Polymorphisms in genes involved in neurotransmission in relation to smoking. Eur J Pharmacol 2000; 410: 215-226.
53. Al Koudsi N, Tyndale RF. Genetic influences on smoking: a brief review. Ther Drug Monit 2005; 27: 704-709.
54. MacLeod SL, Chowdhury P. The genetics of nicotine dependence: relationship to pancreatic cancer. World J Gastroenterol 2006; 12: 7433-7439.
55. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
56. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212-1217.
57. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608-1614.
58. Rao Y, Hoffmann E, Zia M, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747-755.
59. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001; 29: 548-552.
60. Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K, Ohno Y. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J Epidemiol 2003; 13: 176-181.
61. Fujieda M, Yamazaki H, Saito T, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451-2458.
62. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615-626.
63. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353: 898-899.
64. Loriot MA, Rebuissou S, Oscarson M, et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11: 39-44.
65. Carter B, Long T, Cinciripini P. A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 2004; 6: 221-227.
66. Caporaso NE, Lerman C, Audrain J, et al. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers Prev 2001; 10: 261-263.
67. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 2000; 10: 5-10.
68. Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 1996; 6: 261-263.
69. Boustead C, Taber H, Idle JR, Cholerton S. CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics 1997; 7: 411-414.
70. 7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 2004; 50: 124-127.
71. 1 subunit (CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence. Hum Genet 2006; 120: 381-389.
72. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007; 16: 36-49.
73. 2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet 2000; 96: 646-653.
74. 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004; 75: 112-121.
75. 4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 2005; 14: 1211-1219.
76. 2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006; 26: 8707-8714.
77. 2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 596-604.
78. 2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci 2007; 32: 412-416.
79. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-5278.
80. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-257.
81. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 2002; 22: 8785-8789.
82. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob Res 2004; 6: 899-912.
83. Noble EP, St Jeor ST, Ritchie T, et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994; 42: 257-260.
84. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-79.
85. Comings DE, Gade R, Wu S, et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997; 2: 44-56.
86. Shields PG, Lerman C, Audrain J, et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7: 453-458.
87. Spitz MR, Shi H, Yang F, et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998; 90: 358-363.
88. Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1021-1026.
89. Sullivan PF, Neale MC, Silverman MA, et al. An association study of DRD5 with smoking initiation and progression to nicotine dependence. Am J Med Genet 2001; 105: 259-265.
90. Yoshida K, Hamajima N, Kozaki K, et al. Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiol Biomarkers Prev 2001; 10: 403-405.
91. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. Thegenetic basis forsmoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583-597.
92. Laucht M, Becker K, El-Faddagh M, Hohm E, Schmidt MH. Association of the DRD4 exon III polymorphism with smoking in fifteen-year-olds: a mediating role for novelty seeking? J Am Acad Child Adolesc Psychiatry 2005; 44: 477-484.
93. Bierut LJ, Rice JP, Edenberg HJ, et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000; 90: 299-302.
94. Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S. Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998; 8: 125-128.
95. Johnstone EC, Yudkin P, Griffiths SE, Fuller A, Murphy M, Walton R. The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addict Biol 2004; 9: 221-226.
96. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20.
97. Sabol SZ, Nelson ML, Fisher C, et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7-13.
98. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 2004; 4: 102-109.
99. Jorm AF, Henderson AS, Jacomb PA, et al. Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000; 96: 331-334.
100. Vandenbergh DJ, Bennett CJ, Grant MD, et al. Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 2002; 4: 333-340.
101. McKinney EF, Walton RT, Yudkin P, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10: 483-491.
102. Ito H, Hamajima N, Matsuo K, et al. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics 2003; 13: 73-79.
103. Costa-Mallen P, Costa LG, Checkoway H. Genotype combinations for monoamine oxidase-B intron 13 polymorphism and dopamine D2 receptor TaqIB polymorphism are associated with ever-smoking status among men. Neurosci Lett 2005; 385: 158-162.
104. Ma JZ, Beuten J, Payne TJ, Dupont RT, Elston RC, Li MD. Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum Mol Genet 2005; 14: 1691-1698.
105. Freire MT, Marques FZ, Hutz MH, Bau CH. Polymorphisms in the DBH and DRD2 gene regions and smoking behavior. Eur Arch Psychiatry Clin Neurosci 2006; 256: 93-97.
106. Yu Y, Panhuysen C, Kranzler HR, et al. Intronic variants in the dopa decarboxylase (DDC) gene are associated with smoking behavior in European-Americans and African-Americans. Hum Mol Genet 2006; 15: 2192-2199.
107. Zhang H, Ye Y, Wang X, Gelernter J, Ma JZ, Li MD. DOPA decarboxylase gene is associated with nicotine dependence. Pharmacogenomics 2006; 7: 1159-1166.
108. Lerman C, Shields PG, Main D, et al. Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking. Pharmacogenetics 1997; 7: 521-524.
109. Anney RJ, Olsson CA, Lotfi-Miri M, Patton GC, Williamson R. Nicotine dependence in a prospective population-based study of adolescents: the protective role of a functional tyrosine hydroxylase polymorphism. Pharmacogenetics 2004; 14: 73-81.
110. Olsson C, Anney R, Forrest S, et al. Association between dependent smoking and a polymorphism in the tyrosine hydroxylase gene in a prospective population-based study of adolescent health. Behav Genet 2004; 34: 85-91.
111. Colilla S, Lerman C, Shields PG, et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005; 15: 393-398.
112. Redden DT, Shields PG, Epstein L, et al. Catechol-O- methyltransferase functional polymorphism and nicotine dependence: an evaluation of nonreplicated results. Cancer Epidemiol Biomarkers Prev 2005; 14: 1384-1389.
113. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006; 31: 675-684.
114. Guo S, Chen da F, Zhou DF, et al. Association of functional catechol O-methyltransferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology (Berl) 2007; 190: 449-456.
115. Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ. Effects of systemic nicotine on serotonin release in rat brain. Brain Res 1993; 621: 311-318.
116. Mihailescu S, Palomero-Rivero M, Meade-Huerta P, Maza-Flores A, Drucker-Colin R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol 1998; 360: 31-36.
117. Hu S, Brody CL, Fisher C, et al. Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Mol Psychiatry 2000; 5: 181-188.
118. Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields PG. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psychiatry 2000; 5: 189-192.
119. Lerman C, Caporaso NE, Bush A, et al. Tryptophan hydroxylase gene variant and smoking behavior. Am J Med Genet 2001; 105: 518-520.
120. Sullivan PF, Jiang Y, Neale MC, Kendler KS, Straub RE. Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. Am J Med Genet 2001; 105: 479-484.
121. Mizuno S, Ito H, Hamajima N, Tamakoshi A, Hirose K, Tajima K. Association between smoking habits and tryptophan hydroxylase gene C218A polymorphism among the Japanese population. J Epidemiol 2004; 14: 94-99.
122. Lerman C, Shields PG, Audrain J, et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev 1998; 7: 253-255.
123. Ishikawa H, Ohtsuki T, Ishiguro H, et al. Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev 1999; 8: 831-833.
124. Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004; 14: 83-90.
125. Lerman C, Wileyto EP, Patterson F, et al. The functional mopioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4: 184-192.
126. Yudkin P, Munafo M, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 2004; 328: 989-990.
127. Dahl JP, Jepson C, Levenson R, et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J 2006; 6: 194-199.
128. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600-608.
129. Lerman C, Jepson C, Wileyto EP, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006; 31: 231-242.
130. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006; 11: 400-409.
131. Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 398-400.
132. David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 2007; 9: 225-231.
133. Hutchison KE, Allen DL, Filbey FM, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 2007; 64: 1078-1086.
134. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2007; 16: 1065-1069.
135. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2007; 16: 1312-1314.
136. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the m-opioid receptor gene with smoking cessation. Pharmacogenomics J 2007; 7: 353-361.
137. O'Gara C, Stapleton J, Sutherland G, et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 2007; 17: 61-67.
138. Ray R, Jepson C, Wileyto EP, et al. Genetic variation in mopioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res 2007; 9: 1237-1241.
139. David SP,Munafo MR,Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008; 8: 122-128.
140. Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 2008; 18: 121-128.
141. Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627-634.
142. David SP, Niaura R, Papandonatos GD, et al. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?Nicotine Tob Res 2003; 5: 935-942.
143. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-548.
144. Swan GE, Valdes AM, Ring HZ, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005; 5: 21-29.
145. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O- methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61: 111-118.
146. David SP, Brown RA, Papandonatos GD, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9: 821-833.
147. David SP, Strong DR, Munafo MR, et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9: 1251-1257.
148. Lee AM, Jepson C, Hoffmann E, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007; 62: 635-641.
149. Swan GE, Jack LM, Valdes AM, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 2007; 26: 361-368.